Clinical trials: SGLT2-Inhibitors
SGLT-2 Inhibitor, Atrial Fibrillation
The Effect of SGLT-2 Inhibitor in Patient With Atrial Fibrillation and Diabetes Mellitus
This study was designed to compare the effects on atrial rhythm control between SGLT2 inhibitor and other oral hypoglycemic agents in patients with atrial fibrillation and diabetes mellitus.
- Conditions
- SGLT-2 Inhibitor, Atrial Fibrillation, Diabetes Mellitus, Type 2
- Trial name
- NCT05029115
- Testing
- SGLT2 inhibitor
- Where
- South Korea
- Volunteers
- 716 people
- Sponsor
- Ewha Womans University Mokdong Hospital
Type 2 Diabetes Mellitus
Efficacy and Safety Study of TA-7284 in Patients With Type 2 Diabetes
The purpose of this study is to evaluate the efficacy and safety of TA-7284 as monotherapy in patients with type 2 Diabetes for 24 weeks administration.
- Trial name
- NCT01413204
- Testing
- TA-7284 Low, TA-7284 High
- Where
- 5 sites in Japan
- Volunteers
- 272 people
- Sponsor
- Tanabe Pharma Corporation
Type 2 Diabetes
Effects of Diabetes Medications on Adrenal Function and Intestinal Microbiota
The primary aim of this observational study is to describe the effects of glucagon-like peptide-1 (GLP-1) receptor agonists and Sodium-Glucose Co-transporter 2 inhibitors ( SGLT-2 inhibitors) on adrenal function.
- Trial name
- NCT04151849
- Testing
- GLP-1 receptor agonist, SGLT2 inhibitor
- Where
- Estonia
- Volunteers
- 23 people
- Sponsor
- University of Tartu
Type2 Diabetes, Heart Failure With Preserved Ejection Fraction
SGLT2 Inhibitors, Ketones, and Cardiovascular Benefit Research Plan
The study team will examine the effects of SGLT2i (and SGLT2i-induced increases in plasma ketone concentrations) on skeletal muscle and cardiac ketone uptake, skeletal muscle bioenergetics, cardiopulmonary exercise capacity, and…
- Trial name
- NCT05057806
- Testing
- Empagliflozin 25 MG
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Chronic Kidney Disease
SGLT2 Inhibitors and Renal Anemia in Japan: RWD
The objectives of the study are: 1. To evaluate the association between Sodium-Glucose Co-Transporter-2 (SGLT2) inhibitor use and the occurrence of anemia in patients with chronic kidney disease (CKD) using a nested case-control…
- Trial name
- NCT07063316
- Testing
- SGLT2 inhibitor
- Where
- Japan
- Volunteers
- 15,000 people
- Sponsor
- Boehringer Ingelheim
Cancer, Diabetes Mellitus, Type 2
SGLT2 Inhibitors and Reducing the Risk of Cancers Among Diabetics , an Observational Study
Since the discovery of SGLT2 inhibitors, there is a great shift in diabetic treatment, so this drug is magic, this drug can reduce the blood sugar level by blocking the reabsorption of glucose in the kidney and increasing glucose…
- Conditions
- Cancer, Diabetes Mellitus, Type 2, Interleukin 6, SGLT2 Inhibitors
- Trial name
- NCT05612269
- Testing
- interleukin 6
- Where
- Saudi Arabia
- Volunteers
- 200 people
- Sponsor
- Ministry of Health, Saudi Arabia
Coronary Artery Disease
The Effect of SGLT-2 Inhibitors on Epicardial Adipose Tissue and Cardiac Function in T2DM Patients With CAD (EpiCAD)
Sodium-glucose contrasporter-2 (SGLT-2) inhibitors make up an antidiabetic medication that promotes glycosuria. They are known to have an indirect reduction in cardiovascular complications, based on a series of in-depth studies.
- Trial name
- EpiCAD (NCT06128096)
- Testing
- Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor
- Where
- Malaysia
- Volunteers
- 360 people
- Sponsor
- Clinical Research Centre, Malaysia
Type1 Diabetes Mellitus
Effect of SGLT2i in Conjunction With the Artificial Pancreas on Improving the Glycemia in T1DM in the Outpatient Setting
The most advanced configurations of the Artificial Pancreas (AP) have not yet been demonstrated to sufficiently maximize time in target glycemia.
- Trial name
- CLASS17 (NCT03979352)
- Testing
- empagliflozin, artificial pancreas
- Where
- 2 sites in Canada
- Volunteers
- 28 people
- Sponsor
- Samuel Lunenfeld Research Institute, Mount Sinai Hospital
Chronic Coronary Syndrome, Atrial Fibrillation
SGLT2 Inhibitor TrEatment iN Patients Awaiting cOronary arTery bYpass Surgery to Reduce Post-opErative AF
The goal of this randomized, double-blinded, controlled clinical trial is to investigate if treatment with an sodium-glucose cotransporter-2 inhibitor (SGLT2) during the unique time window before coronary artery bypass surgery…
- Trial name
- STENOTYPE (NCT05852704)
- Testing
- Dapagliflozin 10mg Tab
- Where
- 8 sites in Czechia, Denmark and 1 more
- Volunteers
- 800 people
- Sponsor
- Region Örebro County
Diabetes Mellitus, Stroke
Pioglitazone and SGLT2 Inhibitors vs. DPP4 Inhibitors in Patients With Stroke
Introduction: An optimal combination of antidiabetic drugs for diabetic patients with ischemic stroke is not well-established. The objective of this randomized trial is to evaluate whether combination of pioglitazone and a sodium…
- Trial name
- NCT04419337
- Testing
- Metformin plus Pioglitazone plus an SGLT2 inhibitor
- Where
- Taiwan
- Volunteers
- 200 people
- Sponsor
- Chang Gung Memorial Hospital
Acute Kidney Injury, Cardiac
Pre-operative Exposure to SGLT2 Inhibitors and Post-operative Acute Renal Failure in Cardiac Surgery: a Retrospective Monocentric Cohort Study
Cardiac surgery with cardiopulmonary bypass exposes patients to the risk of post-operative acute kidney injury. In the specific setting of cardiac surgery, acute kidney injury is often of multifactorial origindue to particular…
- Conditions
- Acute Kidney Injury, Cardiac, Surgery
- Trial name
- SGLT2i (NCT06453161)
- Testing
- Post-operative acute kidney injury
- Where
- France
- Volunteers
- 500 people
- Sponsor
- Hospices Civils de Lyon
Prediabetes
Evaluation of Empagliflozin vs Standard Care in Veterans With Prediabetes
Prediabetes effects 96 million people 18 years of age or older. It is important to identify treatment options to slow or prevent progression to diabetes.
- Trial name
- PREVNT (NCT06828731)
- Testing
- Empagliflozin 10mg daily, Lifestyle education
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Charles George VA Medical Center
Diabetic Nephropathies
Effect of Sodium Glucose co Transporter 2 Inhibitor ( SGLT2) on Proteinuria in Diabetic Patients
Diabetes Mellitus is the leading cause of end stage renal disease. As proven by many studies , controlling proteinuria can delay the progression to end stage renal disease.This work will study the effect of sodium glucose co…
- Trial name
- NCT03573102
- Testing
- SGLT2 inhibitor, ACE inhibitor
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Nahla H Tohami
Type 2 Diabetes
The Effect of a SGLT2 Inhibitor on Glucose Flux, Lipolysis and Exercise in Type 2 Diabetes
The study is a randomised double blind placebo control cross over trial with 4 weeks washout period. The expected duration of participant participation is 103 days.
- Trial name
- SINGLED (NCT04219124)
- Testing
- IMP oral tablet
- Where
- United Kingdom
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- University of Leicester
Diabetes Mellitus, Type 2
Meta-analysis in Post-marketing Surveillances for SGLT2 Inhibitors in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to integrate the post-marketing surveillances data (Specified use-results surveys on long-term treatment) of the 6 SGLT2 inhibitors approved or applied in Japan and to evaluate the safety and efficacy…
- Trial name
- NCT02284269
- Testing
- SGLT2 Inhibitors
- Volunteers
- 18,000 people
- Sponsor
- Pharmaceuticals and Medical Devices Agency, Japan
Brugada Syndrome (BrS)
Empagliflozin as a Potential Therapeutic Solution for Patients With Brugada Syndrome
The goal of this clinical trial is to learn if Empagliflozin works to treat Brugada syndrome patients by affecting their electrocardiographic (ECG) patterns, and to evaluate its safety.
- Trial name
- NCT07146880
- Testing
- Empagliflozin (EMPA)
- Where
- Taiwan
- Volunteers
- 10 people
- Sponsor
- National Taiwan University Hospital